Current Advances and Future Directions of Pluripotent Stem Cells-Derived Engineered Heart Tissue for Treatment of Cardiovascular Diseases
Authors:
- Xingyu HeXingyu He
- Angela GoodAGAngela Good
- Wael KalouWKWael Kalou
- Waqas AhmadWaqas Ahmad
- Suchandrima DuttaSDSuchandrima Dutta
- Sophie ChenSCSophie Chen
- Charles Noah LinCLCharles Noah Lin
- Karthickeyan Chella KrishnanKKKarthickeyan Chella Krishnan
- Yanbo FanYFYanbo Fan
- Wei HuangWHWei Huang
- Jialiang LiangJialiang Liang
- Yigang WangYigang Wang
Open Access
Abstract
Cardiovascular diseases resulting from myocardial infarction (MI) remain a leading cause of death worldwide, imposing a substantial burden on global health systems. Current MI treatments, primarily pharmacological and surgical, do not regenerate lost myocardium, leaving patients at high risk for heart failure. Engineered heart tissue (EHT) offers a promising solution for MI and related cardiac conditions by replenishing myocardial loss. However, challenges like immune rejection, inadequate vascularization, limited mechanical strength, and incomplete tissue maturation hinder clinical application. The discovery of human-induced pluripotent stem cells (hiPSCs) has transformed the EHT field, enabling new bioengineering innovations. This review explores recent advancements and future directions in hiPSC-derived EHTs, focusing on innovative materials and fabrication methods like bioprinting and decellularization, and assessing their therapeutic potential through preclinical and clinical studies. Achieving functional integration of EHTs in the heart remains challenging due to the need for synchronized contraction, sufficient vascularization, and mechanical compatibility. Solutions such as genome editing, personalized medicine, and AI technologies offer promising strategies to address these translational barriers. Beyond MI, EHTs also show potential in treating ischemic cardiomyopathy, heart valve engineering, and drug screening, underscoring their promise in cardiovascular regenerative medicine.Keywords
Funding Information
- National Institutes of Health (R01HL157456, R01HL168464, R01HL167670, R01HL171495, 968781)
- American Heart Association (R01HL157456, R01HL168464, R01HL167670, R01HL171495, 968781)
This publication has 130 references indexed in Scilit:
- Formulation and Evaluation of PVA/Gelatin/Carrageenan Inks for 3D Printing and Development of Tissue‐Engineered Heart ValvesAdvanced Functional Materials, 2023
- Accelerating cardiovascular research: recent advances in translational 2D and 3D heart modelsEuropean Journal of Heart Failure, 2022
- Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristicsEuropean Journal of Heart Failure, 2021
- Prioritizing Symptom Management in the Treatment of Chronic Heart FailureESC Heart Failure, 2020
- Electrospun Fibrous Architectures for Drug Delivery, Tissue Engineering and Cancer TherapyAdvanced Functional Materials, 2018
- Self‐Assembling Peptides as Cell‐Interactive ScaffoldsAdvanced Functional Materials, 2011
- Progress in the Field of Electrospinning for Tissue Engineering ApplicationsAdvanced Materials, 2009
- Electrospun scaffold tailored for tissue‐specific extracellular matrixBiotechnology Journal, 2006
- Optimization of cardiac cell seeding and distribution in 3D porous alginate scaffoldsBiotechnology and Bioengineering, 2002
- Three-dimensional engineered heart tissue from neonatal rat cardiac myocytesBiotechnology and Bioengineering, 2000